TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07270731: Investigation of Safety, Tolerability, Pharmacokinetic and Pharmacodynamics of Single Administrations of NNC9733-0001 in Healthy Participants and in Participants With Type 2 Diabetes

Sponsor: Novo Nordisk A/S · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 60 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$7,224,320

Rescue Site Savings

+$4,763,536

Unlock Full NCT07270731 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07270731 Rescue Dossier →